Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Fortress Biotech (FBIO) Gross Margin (2016 - 2025)

Fortress Biotech (FBIO) has 11 years of Gross Margin data on record, last reported at 66.2% in Q3 2025.

  • For Q3 2025, Gross Margin rose 232.0% year-over-year to 66.2%; the TTM value through Sep 2025 reached 262.47%, up 35359.0%, while the annual FY2024 figure was 1291.93%, 95412.0% down from the prior year.
  • Gross Margin reached 66.2% in Q3 2025 per FBIO's latest filing, down from 69.91% in the prior quarter.
  • Across five years, Gross Margin topped out at 111.41% in Q4 2024 and bottomed at 1222.88% in Q2 2022.
  • Average Gross Margin over 5 years is 4.09%, with a median of 58.06% recorded in 2021.
  • Peak YoY movement for Gross Margin: tumbled -128093bps in 2022, then skyrocketed 127820bps in 2023.
  • A 5-year view of Gross Margin shows it stood at 47.88% in 2021, then grew by 11bps to 52.95% in 2022, then soared by 100bps to 105.64% in 2023, then rose by 5bps to 111.41% in 2024, then tumbled by -41bps to 66.2% in 2025.
  • Per Business Quant database, its latest 3 readings for Gross Margin were 66.2% in Q3 2025, 69.91% in Q2 2025, and 63.54% in Q1 2025.